Mount Sinai Launches the i3 Asset Accelerator to Advance the Development of Life-Saving Discoveries
The Icahn School of Medicine at Mount Sinai and Mount Sinai Innovation Partners today announced the launch of the i3 Asset Accelerator, a new fund that fast-tracks select research discoveries to reach patients sooner, and has selected its first two projects to receive funding in 2018.
“This initiative will foster great discoveries, bringing them to life and to patients in great speed,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs for the Mount Sinai Health System. The i3 Asset Accelerator is very important to us; it’s what we're all about, taking great science and helping our patients.”
i3 was established with an initial investment of $10 million to advance innovative health care discoveries from Mount Sinai researchers, and philanthropic efforts began to increase its size even prior to its launch. With an advisory team of more than 40 scientists, business professionals, and commercialization experts, i3 provides nascent Mount Sinai technologies with the funding necessary to propel their development jointly with contract research organizations, rapidly develop commercially relevant data, and quickly partner with existing companies, startups, or professional investors through a milestone-based development strategy.
“i3 provides funding to accelerate commercially relevant research,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners. “It allows us to de-risk technology, helps us find more partners, and at the same time generates rewards in terms of patient benefits for the future.”
The two initial projects chosen by i3 represent diverse areas of health care technology:
i) A new treatment for cancer using a novel platform technology to develop new drugs by Ross Cagan, PhD, Senior Associate Dean for the Icahn School of Medicine’s Graduate School of Biomedical Sciences and Professor of Ophthalmology, Oncological Sciences, and Cell, Development and Regenerative Biology, in collaboration with Arvin Dar, PhD, Assistant Professor of Oncological Sciences and Pharmacological Sciences.
ii) The development of new therapies for influenza B viral infections by Florian Krammer, PhD, Associate Professor of Microbiology.
“i3 offers the opportunity for advancing commercially relevant solutions to patients on a global scale,” Dr. Lium said. “i3 is the next step in engaging with our community, building upon our translational competencies, and evolving our commercial ecosystem to create major breakthroughs in health care.”
To learn more about the i3 Asset Accelerator, visit ip.mountsinai.org/about-i3-accelerator.
About Mount Sinai Innovation Partners (MSIP)
MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit www.ip.mountsinai.org.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
The Mount Sinai Hospital Ranked Among World’s Best in Newsweek/Statista Rankings
Mar 10, 2025 View All Press Releases
Mount Sinai Expands Psychedelic Research Center With New Facility in Upper Manhattan
Sep 19, 2024 View All Press Releases